Clinical Trials
11 trialsNCT00804856 2023-10-03
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Boehringer Ingelheim
Phase 2 Completed
NCT01721876 2023-02-08
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Boehringer Ingelheim
Phase 3 Completed
NCT01957644 2019-02-08
Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML
Boehringer Ingelheim
Phase 1 Terminated
NCT01662505 2018-07-30
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
Boehringer Ingelheim
Phase 1 Completed
NCT01971476 2018-07-30
Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known
Boehringer Ingelheim
Phase 1 Completed
NCT02201329 2018-07-30
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Boehringer Ingelheim
Phase 1 Completed
NCT02905994 2018-05-04
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
Massachusetts General Hospital
Phase 1 Withdrawn
NCT02198482 2018-02-28
Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
University of Ulm
Phase 2 Terminated
NCT02527174 2017-04-05
VIAC
University of Alberta
Phase 1 Withdrawn
NCT02722135 2017-01-27
A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy Failed
Boehringer Ingelheim
Phase 1 Withdrawn
NCT02861040 2016-12-15
Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Northwestern University
Phase 1 Withdrawn